162 related articles for article (PubMed ID: 36572733)
1. Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre.
Scheiter A; Hierl F; Lüke F; Keil F; Heudobler D; Einhell S; Klier-Richter M; Konstandin NP; Weber F; Scheiter A; Kandulski A; Schlosser S; Cosma LS; Tews H; Weiss ARR; Grube M; Bumes E; Hau P; Proescholdt M; Steger F; Troeger A; Haferkamp S; Reibenspies LE; Schnabel MJ; Schulz C; Drexler K; Hatzipanagiotou ME; Seitz S; Klinkhammer-Schalke M; Unberath P; Calvisi DF; Pukrop T; Dietmaier W; Evert M; Utpatel K
Br J Cancer; 2023 Apr; 128(6):1134-1147. PubMed ID: 36572733
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
[TBL] [Abstract][Full Text] [Related]
3. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
4. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
5. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW; Kaye TF; Adamson DJ; Tait IS; Polignano FM; Highley MS
J Gastrointest Cancer; 2007; 38(2-4):108-14. PubMed ID: 19089662
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
Chiu CT; Chiang JM; Yeh TS; Tseng JH; Chen TC; Jan YY; Chen MF
Dig Liver Dis; 2008 Sep; 40(9):749-54. PubMed ID: 18329969
[TBL] [Abstract][Full Text] [Related]
7. Infiltration of peritumoural but tumour-free parenchyma with IgG4-positive plasma cells in hilar cholangiocarcinoma and pancreatic adenocarcinoma.
Resheq YJ; Quaas A; von Renteln D; Schramm C; Lohse AW; Lüth S
Dig Liver Dis; 2013 Oct; 45(10):859-65. PubMed ID: 23602806
[TBL] [Abstract][Full Text] [Related]
8. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Kuhlmann JB; Euringer W; Spangenberg HC; Breidert M; Blum HE; Harder J; Fischer R
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):437-43. PubMed ID: 22261548
[TBL] [Abstract][Full Text] [Related]
9. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
10. Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma.
Cheng J; Mao Y; Hong W; Hu W; Shu P; Huang K; Yu J; Jiang M; Li L; Wang W; Ni D; Li S
J Transl Med; 2022 Jun; 20(1):272. PubMed ID: 35705951
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic cholangiocarcinoma.
Brown KM; Parmar AD; Geller DA
Surg Oncol Clin N Am; 2014 Apr; 23(2):231-46. PubMed ID: 24560108
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
13. Multi-detector spiral CT diagnosis of common bile duct ampullary carcinoma.
Zhao DZ; Guo Y; Sun YP; Liu HM; Zhang Z; Ma QL; Wang YS; Chen CL
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3549-3553. PubMed ID: 28925490
[TBL] [Abstract][Full Text] [Related]
14. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.
Collins AL; Wojcik S; Liu J; Frankel WL; Alder H; Yu L; Schmittgen TD; Croce CM; Bloomston M
Ann Surg Oncol; 2014 Jan; 21(1):133-8. PubMed ID: 24046106
[TBL] [Abstract][Full Text] [Related]
15. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
[TBL] [Abstract][Full Text] [Related]
17. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
[TBL] [Abstract][Full Text] [Related]
18. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma.
Goeppert B; Frauenschuh L; Renner M; Roessler S; Stenzinger A; Klauschen F; Warth A; Vogel MN; Mehrabi A; Hafezi M; Boehmer K; von Deimling A; Schirmacher P; Weichert W; Capper D
Mod Pathol; 2014 Jul; 27(7):1028-34. PubMed ID: 24309328
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience.
Wang L; Zhu H; Zhao Y; Pan Q; Mao A; Zhu W; Zhang N; Lin Z; Zhou J; Wang Y; Zhang Y; Wang M; Feng Y; He X; Xu W; Wang L
J Transl Med; 2020 Jul; 18(1):273. PubMed ID: 32631434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
